• Kewal K. Jain
Part of the Springer Protocols Handbooks book series (SPH)


The usual definition of a neuroprotectant is an agent is that aims to prevent neuronal death by inhibiting one or more of the pathophysiological steps in the processes that follow injury to the nervous system or ischemia due to occlusion of an artery or hypoxia due to any cause. This definition has now been extended to include protection against neurodegeneration and neurotoxins. The extended definition includes interventions that slows or halt the progression of neuronal degeneration. This book will describe the natural mechanisms of neuroprotection, agents used as neuroprotectives and therapeutic neuroprotection in all neurological disorders where there is danger of progression of neurological damage regardless of the pathological process or clinical features. Prophylactic neuroprotection during anesthesia and surgery is also discussed. Neuroprotection may also be used for prevention of progression of a disease if it can be identified at a presymptomatic stage. The term neuroprotective, although an adjective, will be used as a noun in preference to neuroprotectant.


  1. Ali T, Kim MJ, Rehman SU, et al. Anthocyanin-Loaded PEG-Gold Nanoparticles Enhanced the Neuroprotection of Anthocyanins in an Aβ1–42 Mouse Model of Alzheimer’s Disease. Mol Neurobiol 2017;54:6490–6506.CrossRefGoogle Scholar
  2. Ames A, Wright RL, Kowada M, et al. Cerebral ischemia II: the no reflow phenomenon. Am J Pathol 1968;52:437–447.PubMedPubMedCentralGoogle Scholar
  3. Arbo BD, Benetti F, Ribeiro MF. Astrocytes as a target for neuroprotection: Modulation by progesterone and dehydroepiandrosterone. Prog Neurobiol 2016;144:27–47.CrossRefGoogle Scholar
  4. Arnfred I, Secher O. Anoxia and barbiturates. tolerance to anoxia in mice influenced by barbiturates. Arch Int Pharmacodyn Ther 1962;139:67–74.Google Scholar
  5. Asatryan A, Bazan NG. Molecular mechanisms of signaling via the docosanoid neuroprotectin D1 for cellular homeostasis and neuroprotection. J Biol Chem 2017;292:12390–12397.CrossRefGoogle Scholar
  6. Bain L, Keren NI, Posey Norris SM (reporters). Biomarkers of Neuroinflammation: Proceedings of a Workshop. Washington, DC: National Academies Press, 2017.Google Scholar
  7. Banerjee A, Ghatak S, Sikdar SK. l-Lactate mediates neuroprotection against ischaemia by increasing TREK1 channel expression in rat hippocampal astrocytes in vitro. J Neurochem 2016;138:265–81.CrossRefGoogle Scholar
  8. Braniste V, Al-Asmakh M, Kowal M, et al. The gut microbiota influences blood-brain barrier permeability in mice. Science Translational Medicine 2014;6:263ra158.CrossRefGoogle Scholar
  9. Chen L, Stone MC, Tao J, Rolls MM. Axon injury and stress trigger a microtubule-based neuroprotective pathway. Proc Natl Acad Sci U S A 2012;109:11842–7.CrossRefGoogle Scholar
  10. Chen YC, Tsai CL, Wei YH, et al. ATOH1/RFX1/RFX3 transcription factors facilitate the differentiation and characterisation of inner ear hair cell-like cells from patient-specific induced pluripotent stem cells harbouring A8344G mutation of mitochondrial DNA. Cell Death Dis 2018;9:437.CrossRefGoogle Scholar
  11. Cheng X, Mukhtar M, Acheampong EA, et al. HIV-1 Vpr Potently Induces Programmed Cell Death in the CNS in Vivo. DNA and Cell Biology 2007;26:116–31.CrossRefGoogle Scholar
  12. Chonpathompikunlert P, Fan CH, Ozaki Y, et al. Redox nanoparticle treatment protects against neurological deficit in focused ultrasound-induced intracerebral hemorrhage. 2012;7:1029–43.Google Scholar
  13. Curtis DR, Phillis JW, Watkins JC. Chemical excitation of spinal neurons. Nature 1959;183:611.CrossRefGoogle Scholar
  14. de la Grange P, Gratadou L, Delord M, et al. Splicing factor and exon profiling across human tissues. Nucleic Acids Res 2010;38:2825–38.CrossRefGoogle Scholar
  15. Echouffo-Tcheugui JB, Conner SC, Himali JJ, et al. Circulating cortisol and cognitive and structural brain measures: The Framingham Heart Study. Neurology 2018;91:e1961–e1970.CrossRefGoogle Scholar
  16. Elliott-Hunt CR, Holmes FE, Hartley DM, et al. Endogenous galanin protects mouse hippocampal neurons against amyloid toxicity in vitro via activation of galanin receptor-2. J Alzheimers Dis 2011;25:455–62.CrossRefGoogle Scholar
  17. Estevez AY, Pritchard S, Harper K, et al. Neuroprotective mechanisms of cerium oxide nanoparticles in a mouse hippocampal brain slice model of ischemia. Free Radic Biol Med 2011;51:1155–63.CrossRefGoogle Scholar
  18. Eugene AR, Masiak J. The Neuroprotective Aspects of Sleep. MEDtube Sci 2015;3:35–40.PubMedPubMedCentralGoogle Scholar
  19. Fay T. Observations on generalized refrigeration in cases of severe cerebral trauma. Assoc Res Nerv Ment Dis Proc 1943;24:611–619.Google Scholar
  20. Gaudin A, Yemisci M, Eroglu H, et al. Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury. Nat Nanotechnol 2014;9:1054–1062.CrossRefGoogle Scholar
  21. Haskew-Layton RE, Payappilly JB, Smirnova NA, et al. Controlled enzymatic production of astrocytic hydrogen peroxide protects neurons from oxidative stress via an Nrf2-independent pathway. Proc Natl Acad Sci USA 2010;107:17385–90.CrossRefGoogle Scholar
  22. Howard RS, Holmes PA, Siddiqui A, et al. Hypoxic–ischaemic brain injury: imaging and neurophysiology abnormalities related to outcome. QJM 2012;105:551–61.CrossRefGoogle Scholar
  23. Jain KK. Current Status and Future Prospects of Nanoneurology. J Nanoneuroscience 2009;1:56–64.CrossRefGoogle Scholar
  24. Jain KK. Drug-induced Neurological Disorders. 3rd edition, Hogrefe, Göttingen, 2012.Google Scholar
  25. Jain KK. Applications of Biotechnology in Neurology. Springer, New York, 2013.CrossRefGoogle Scholar
  26. Jain KK. Handbook of Nanomedicine, 3rd ed. Springer, New York, 2017.CrossRefGoogle Scholar
  27. Jain KK. Biomarkers of Disorders of the Nervous System. In: Jain KK. Handbook of Biomarkers, 2nd ed. Springer, New York, 2017a:463–610.CrossRefGoogle Scholar
  28. Jain KK. Blood-Brain Barrier. In, Roos RP (ed) MedLink Neurology. Medlink Publishing Corporation, San Diego, California, 2019.Google Scholar
  29. Jain KK. Neurotrophic Factors. In Roos RP (ed) MedLink Neurology. Medlink Publishing Corporation, San Diego, California, 2019a.Google Scholar
  30. Jain KK. Drug Delivery in CNS Disorders. Jain PharmaBiotech Publications, Basel, 2019b.Google Scholar
  31. Jain KK. Nanobiotechnology: applications, companies and markets. Jain PharmaBiotech Publications, Basel, 2019c.Google Scholar
  32. Jeong JK, Park SY. Neuroprotective effect of cellular prion protein (PrPC) is related with activation of alpha7 nicotinic acetylcholine receptor (α7nAchR)-mediated autophagy flux. Oncotarget 2015;6:24660–74.PubMedPubMedCentralGoogle Scholar
  33. Jessen NA, Munk AS, Lundgaard I, Nedergaard M. The Glymphatic System: A Beginner’s Guide. Neurochem Res 2015;40:2583–99.CrossRefGoogle Scholar
  34. Lazorthes G, Campan L. Moderate hypothermia in the treatment of head injuries. Clin Neurosurg 1964;12:293–299.CrossRefGoogle Scholar
  35. Li JW, Li LL, Chang LL, et al. Stem cell factor protects against neuronal apoptosis by activating AKT/ERK in diabetic mice. Braz J Med Biol Res 2009;42:1044–9.CrossRefGoogle Scholar
  36. Li M, Li Z, Yao Y, et al. Astrocyte-derived interleukin-15 exacerbates ischemic brain injury via propagation of cellular immunity. Proc Natl Acad Sci U S A 2017;114:E396–E405.CrossRefGoogle Scholar
  37. Lichtenauer M, Zimmermann M, Nickl S, et al. Transient hypoxia leads to increased serum levels of heat shock protein-27, -70 and caspase-cleaved cytokeratin 18. Clin Lab 2014;60:323–8.CrossRefGoogle Scholar
  38. Lukyanova LD, Kirova YI. Mitochondria-controlled signaling mechanisms of brain protection in hypoxia. Front Neurosci 2015;9:320.CrossRefGoogle Scholar
  39. Luo W, Wang Y, Reiser G. Protease-activated receptors in the brain: receptor expression, activation, and functions in neurodegeneration and neuroprotection. Brain Res Rev 2007;56:331–45.CrossRefGoogle Scholar
  40. Matsui T, Omuro H, Liu YF, et al. Astrocytic glycogen-derived lactate fuels the brain during exhaustive exercise to maintain endurance capacity. Proc Natl Acad Sci U S A. 2017;114:6358–6363.CrossRefGoogle Scholar
  41. Mudò G, Mäkelä J, Di Liberto V, et al. Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease. Cell Mol Life Sci 2012;69:1153–65.CrossRefGoogle Scholar
  42. Musiek ES, Lim MM, Yang G, et al. Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. J Clin Invest 2013;123:5389–400.CrossRefGoogle Scholar
  43. Neubauer RA, End E. Hyperbaric oxygen as an adjunct therapy in strokes due to thrombosis. Stroke 1980;11:p297.CrossRefGoogle Scholar
  44. Nilewski LG, Sikkema WK, Kent TA, Tour JM. Carbon nanoparticles and oxidative stress: could an injection stop brain damage in minutes? Nanomedicine (Lond) 2015;10:1677–9.CrossRefGoogle Scholar
  45. Posada-Duque RA, Palacio-Castañeda V, Cardona-Gómez GP. CDK5 knockdown in astrocytes provide neuroprotection as a trophic source via Rac1. Mol Cell Neurosci 2015;68:151–66.CrossRefGoogle Scholar
  46. Price JC, Waelsch H, Putnam TJ. DL-glutamic acid hydrochloride in the treatment of petit mal and psychomotor seizures. JAMA 1943;122:1153–1156.CrossRefGoogle Scholar
  47. Reddy MK, Wu L, Kou W, et al. Superoxide dismutase-loaded PLGA nanoparticles protect cultured human neurons under oxidative stress. Appl Biochem Biotechnol 2008;151(2–3):565–77.CrossRefGoogle Scholar
  48. Reid C. Excited states in Chemistry and Biology. London, Butterworths, 1957.Google Scholar
  49. Risher WC, Andrew RD, Kirov SA. Real-time passive volume responses of astrocytes to acute osmotic and ischemic stress in cortical slices and in vivo revealed by two-photon microscopy. Glia 2009;57:207–21.CrossRefGoogle Scholar
  50. Rzigalinski BA, Carfagna CS, Ehrich M. Cerium oxide nanoparticles in neuroprotection and considerations for efficacy and safety. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2017;9(4). doi: E-publication.Google Scholar
  51. Silverstein FS, Buchanan K, Hudson C, et al. Flunarizine limits hypoxia-ischemia induced morphologic injury in immature rat brain. Stroke 1986;17:477–82.CrossRefGoogle Scholar
  52. Stetler RA, Gao Y, Zukin RS, et al. Apurinic/apyrimidinic endonuclease APE1 is required for PACAP-induced neuroprotection against global cerebral ischemia, PNAS 2010;107:3204–9.CrossRefGoogle Scholar
  53. Stetler RA, Gao Y, Leak RK, et al. APE1/Ref-1 facilitates recovery of gray and white matter and neurological function after mild stroke injury. Proc Natl Acad Sci U S A 2016;113:E3558–67.CrossRefGoogle Scholar
  54. Sun XD, Li L, Liu F, et al. Lrp4 in astrocytes modulates glutamatergic transmission. Nat Neurosci 2016;19:1010–8.CrossRefGoogle Scholar
  55. Surnar B, Basu U, Banik B, et al. Nanotechnology-mediated crossing of two impermeable membranes to modulate the stars of the neurovascular unit for neuroprotection. Proc Natl Acad Sci U S A 2018;115:E12333–E12342.CrossRefGoogle Scholar
  56. Symon L. The concept of threshold of ischemia in relation to brain structures and function. J Clin Pathol 1976;11(suppl):149–154.Google Scholar
  57. Tomasia D, Wang GJ, Volkow ND. Energetic cost of brain functional connectivity. Proc Natl Acad Sci U S A 2013 13;110:13642–7.CrossRefGoogle Scholar
  58. Ulivieri C, Savino MT, Luccarini I, et al. The Adaptor Protein Rai/ShcC Promotes Astrocyte-Dependent Inflammation during Experimental Autoimmune Encephalomyelitis. J Immunol 2016;197:480–90.CrossRefGoogle Scholar
  59. Volakakis N, Kadkhodaei B, Joodmardi E, et al. NR4A orphan nuclear receptors as mediators of CREB-dependent neuroprotection. PNAS 2010;107:12317–22.CrossRefGoogle Scholar
  60. Yemisci M, Caban S, Gursoy-Ozdemir Y, et al. Systemically administered brain-targeted nanoparticles transport peptides across the blood-brain barrier and provide neuroprotection. J Cereb Blood Flow Metab 2015;35:469–75.CrossRefGoogle Scholar
  61. Yoo SI, Yang M, Brender JR, et al. Inhibition of Amyloid Peptide Fibrillation by Inorganic Nanoparticles: Functional Similarities with Proteins. Angew Chem Int Ed Engl 2011; 50:5110–5.CrossRefGoogle Scholar
  62. Yu Z, Poppe JL, Wang X. Mitochondrial mechanisms of neuroglobin’s neuroprotection. Oxid Med Cell Longev 2013;2013:756989.CrossRefGoogle Scholar
  63. Zhang H, Xiao J, Hu Z, et al. Blocking transient receptor potential vanilloid 2 channel in astrocytes enhances astrocyte-mediated neuroprotection after oxygen-glucose deprivation and reoxygenation. Eur J Neurosci 2016;44:2493–2503.CrossRefGoogle Scholar
  64. Zheng S, Eacker SM, Hong SJ, et al. NMDA-induced neuronal survival is mediated through nuclear factor I-A in mice. J Clin Invest 2010;120:2446–56.CrossRefGoogle Scholar
  65. Zheng B, Liao Z, Locascio JJ, et al. PGC-1α, a potential therapeutic target for early intervention in Parkinson’s disease. Sci Transl Med 2010a;2(52):52ra73.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Kewal K. Jain
    • 1
  1. 1.Jain PharmaBiotechBaselSwitzerland

Personalised recommendations